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Introduction
The incidence of diabetes is increasing at epidemic rates.
There currently are an estimated 17 million individuals
with diabetes in the United States and this number is
rapidly increasing [1]. The likelihood of developing
diabetes is approximately 40% in persons born after
the year 2000 [2] and is more prevalent among African
Americans, Hispanics and Native Americans [2]. The
personal and national loss of productivity is immense
[3]. The American Diabetes Association estimates that
diabetes cost the United States an estimated $132 billion
in 2002, $92 billion in direct medical expenditures and
$40 billion due to lost work time, disability, and premature
mortality [4].
The morbidity of diabetes is due to both macrovas-
cular and microvascular complications. A diabetic indi-
vidual is 2 to 4 times more likely to have accelerated
atherogenesis of large vessels leading to myocardial in-
farction, stroke and peripheral vascular occlusive disease
[3]. These macrovascular complications can occur in in-
dividuals without diabetes, although it is clear that dia-
betes exacerbates and accelerates atherogenesis. In con-
trast, microvascular complications are more unique to the
diabetic state and eventually occur in nearly all patients
with diabetes. Fifteen years after diagnosis, 90% of pa-
tients have evidence of diabetic retinopathy, the cause of
approximately 25,000 new cases of blindness per year in
the United States [5]. Diabetes is the primary cause of
renal failure and accounts for 40% of new cases requir-
ing dialysis in the United States each year [4]. More than
half of all individuals with diabetes develop neuropathy
[4,6] with a lifetime risk of one or more lower extremity
amputations estimated at 15% [7]. The current article will
focus on this last complication, diabetic neuropathy (DN),
with the goal of introducing new ideas on the pathogenesis
and potential treatment of this disabling complication of
diabetes.
Diabetic Neuropathy (DN)
In 1983, results from the Diabetes Control and Complica-
tions Trial (DCCT) established that hyperglycemia is piv-
otal in the development and progression of DN [8]. The
DCCT enrolled patients with type 1 diabetes. Because the
primary outcome of the DCCT was retinopathy, subjects
were recruited, assigned and randomized within 2 cohorts
depending on baseline retinopathy status. Patients in the
primary prevention cohort had no retinopathy, diabetes
duration of less than 5 years and a urinary albumin excre-
tion rate less than 40 mg/24 h. Patients in the secondary
prevention cohort had mild to moderate nonproliferative
retinopathy, diabetes duration of less than 15 years and a
urinary albumin excretion rate less than 200 mg/24 h. Sub-
jects in the primary and secondary prevention cohorts were
randomized to intensive versus conventional therapy. Dur-
ing the 6.5 year mean follow-up, this translated into a 33%
reduction in mean blood glucose from approximately 230
mg/dL in the conventional treatment groups to approxi-
mately 155 mg/dL in the intensive treatment groups, with
respective HbA1c values of 9% versus 7.2%. DN was di-
agnosed by history, focused neurological examination and
nerve conduction studies. The risk of developing DN was
reduced in the intensive treatment group by 69% in the
primary prevention cohort and 57% in the secondary pre-
vention cohort, with an overall risk reduction of 60% [9].
After completion of the DCCT, long-term observa-
tional follow-up of 1,375 of the 1,425 DCCT patients oc-
curred in the EDIC study [10]. DN was followed in EDIC
using the Michigan Neuropathy Screening Instrument, a
validated tool for the diagnosis of DN [11]. DN was as-
sessed annually during EDIC using this instrument. While
glycemic control merged in EDIC with an average HbA1c
of 8% for both the intensive and conventional treatment
arms, the beneficial effects of prior intensive treatment
has persisted for 8 years. Patients in the initial DCCT-
intensive cohort have approximately a 30% risk reduction
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for developing DN when compared to patients in the ini-
tial DCCT-conventional cohort [12]. This phenomenon is
termed metabolic memory, and implies that the salutary
effects of early glycemic control persist over many years.
How Does Hyperglycemia Cause
Diabetic Neuropathy?
The scientific breadth of diabetes research has expanded
with the recent advances in molecular biology. These in-
vestigations have extended diabetes-related research in
neuropathy to a new fundamental scientific level where
formerly distinct hypotheses are now linked by common
molecular mechanisms and investigative techniques. It is
now generally held that all mechanisms that are contrib-
utory to the onset and progression of diabetic neuropathy
are related in some way to oxidative stress [13]. This article
will focus on the loss of function and survival of neurons
as a cause of diabetic neuropathy, however, it is essential
to consider other potential mechanisms. During diabetes
there is also impaired neuronal regeneration, particularly
of thinly myelinated fibers. In patients with diabetic neu-
ropathy there is evidence of simultaneous neuronal de-
generation and regeneration suggesting that there is an
ongoing dynamic balance between glucose mediated in-
jury and attempts of the neuron for self repair [14]. Studies
have shown that over time the balance shifts toward de-
generation and nerve fibers lose their ability to regenerate.
The mechanisms leading to regenerative impairment are
likely similar to those leading to neuronal dysfunction and
studies linking oxidative stress to impaired regeneration
would prove useful to the study of diabetic neuropathy.
The Chemisty of Oxidative Stress
The production of reactive oxygen species (ROS) is un-
der tight control in normal neurons. There are several free
radical species that are produced normally in neurons to
perform specific functions, including superoxide and hy-
drogen peroxide [15]. While these free radicals are essen-
tial for normal cell function, they can also accelerate the
neuronal dysfunction.
Superoxide
Superoxide is generated by the mitochondrial electron
transfer chain when NADH is oxidized to NAD+. It is
estimated that 4% of electrons that enter the respiratory
chain lead to the formation of superoxide [16]. While su-
peroxide is essential for cell survival, excess superoxide
is injurious [17]. This can occur when cells are exposed
to surplus glucose that in turn impairs mitochondrial elec-
tron transfer chain by inhibiting ATP synthase. This leads
to slowing of electron transfer. Slowed electron transfer
leads to the increased release of electrons that combine
with molecular oxygen to produce superoxide [18]. A sec-
ond consequence of slowed mitochondrial electron trans-
fer is the activation of NADH oxidase, a consequence of
the inability of electron transfer to generate NAD+. Acti-
vated NADH oxidase generates superoxide as a byprod-
uct [19,20]. Activation of this enzyme contributes to neu-
rovascular deficits in diabetic rats through increased ROS
[21].
Hydrogen peroxide
Superoxide is converted to hydrogen peroxide and water
by a family of enzymes known as superoxide dismu-
tase (SOD). Excess superoxide leads to excess hydrogen
peroxide. Hydrogen peroxide is highly diffusable across
membranes [22]. Because hydrogen peroxide has the po-
tential to easily oxidize multiple cellular components, neu-
rons express abundant anti-oxidants that convert hydrogen
peroxide to water. The anti-oxidants include catalase, glu-
tathione and thioredoxin.
Cellular Injury Due to ROS
Both excess superoxide and hydrogen peroxide are inju-
rious to neurons. When superoxide combines with nitric
oxide (NO) highly reactive peroxynitrite forms that attacks
and disrupts proteins and lipids [23]. Superoxide can also
attack the iron sulfur center of particular enzymes leading
to enzyme inhibition. Several key enzymes are sensitive to
this type of attack including complexes 1–3 of the electron
transfer chain and aconitase of the TCA cycle [23].
Unchecked, hydrogen peroxide can react with free iron
and produce hydroxyl radicals. Lipids are major targets of
hydroxyl radical attack [24]. Lipids undergo peroxidation
and form what are known as lipid peroxides. Lipid per-
oxides are directly toxic to cells and mediate cell death.
When proteins and nucleic acids undergo peroxidation and
nitrosylation, they can accumulate and overload the abil-
ity of the cell to recycle them [25]. In addition, damage
to nucleic acids can activate the mechanisms of apopto-
sis [25]. Collectively, accumulation of damaged proteins,
lipids and nucleic acids lead to loss of neuronal function.
There is also now well established oxidative modifica-
tion by superoxide and hydrogen peroxide of transcrip-
tion factors that lead to decreased expression of many
key proteins needed for cell survival, including complex
1 and bcl-2 [24]. In turn, oxidative stress may increase
the gene expression of several pro-apoptotic proteins in-
cluding JNK kinase, poly ADP polyribose polymerase and
cyclooxygenase-2 [26]. Mitochondrial in neurons may be
particularly sensitive to oxidative damage [27,28]. This in
turn could impair the normal energy regulatory function
in neurons which is highly critical to their survival. Thus,
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in neurons, oxidative stress leads to damage of proteins,
lipids, transcription factors and mitochondrial DNA as
well as increased expression of pro-apoptotic proteins.
These interlinked processes are injurious to the nervous
system, slowing axonal transport, altering neuronal sig-
naling and promoting neuronal dysfunction.
Cellular Anti-Oxidant Defense
An anti-oxidant is defined as a compound that can ter-
minate radical chain reactions by donating at least one
hydrogen atom to a free radical [29]. A second type of
anti-oxidant prevents the initiation of a free radical chain
reaction. Cells maintain needed levels of anti-oxidants,
frequently referred to as the cellular anti-oxidant poten-
tial, through both de novo synthesis as well as dietary
intake. Excess ROS can deplete the anti-oxidant poten-
tial of a cell resulting in oxidative stress and the sequelae
of unchecked ROS [30]. Vitamin C and vitamin E are
the common dietary anti-oxidants for mammalian cells
[31]. Vitamin C (ascorbic acid) scavenges an array of ROS
including, hydroxyl, alkoxyl, peroxyl, superoxide anion,
hydroperoxyl radicals and reactive nitrogen radicals such
as nitrogen dioxide, nitroxide, and peroxynitrite at very
low concentrations. In addition ascorbic acid regener-
ates other antioxidants such as α-tocopheroxyl, urate and
β-carotene radical cation from their radical species [29].
The principal role of vitamin E (the generic name for the
family of tocopherol related compounds) as an antioxi-
dant is in scavenging lipid peroxyl radical intermediates
and thereby blocking lipid peroxidation [31]. Tocopherols
also react with other reactive oxidants, including singlet
oxygen, alkoxyl radicals, peroxynitrite, nitrogen dioxide,
ozone, and superoxide.
Glutathione (GSH) is the most important cellular anti-
oxidant for neurons [32]. As discussed above, SOD is a
key enzyme in cellular detoxification. SOD detoxifies su-
peroxide into hydrogen peroxide, which is reduced in the
mitochondria by GSH. Reduction (detoxification) of hy-
drogen peroxide generates an oxidized glutathione disul-
fide. To regenerate glutathione, glutathione disulfide is re-
duced by NADPH [33]. In diabetes, conversion of glucose
to sorbitol is linked to the oxidation of NADPH to NADP+.
This leads to depletion of the NADPH needed for regener-
ating GSH [13,34]. GSH is also necessary to keep protein
thiol groups in their reduced form and to combine with
lipid peroxides to form an inert lipid hydroxyl group in
water [32].
Anti-oxidant potential of the cells is augmented by the
presence of enzymes that synthesize and maintain anti-
oxidant molecules [35]. These include enzymes that syn-
thesize and regenerate GSH and the closely related thiore-
doxin. In addition, there are enzymes that detoxify specific
ROS. SOD and catalase are the key enzymes present, each
with specific ROS targets. SOD converts superoxide to
hydrogen peroxide and water. Catalase converts hydro-
gen peroxide to water and therefore its activity is required
when SOD is active.
Production of ROS in Diabetes
The pathogenesis of diabetic neuropathy has been a source
of controversy and intense investigation. While there are
several theories on how excess glucose injures the ner-
vous system, 3 areas have been the focus of the most
intense investigation. These are (1) accumulation of ad-
vanced glycation end products (AGEs), (2) unchecked ac-
tivity of the polyol pathway, and (3) activation of protein
kinase (PK) C. Oxidative stress provides a unifying mech-
anism for these divergent theories, and is now well doc-
umented to occur as a result of AGE formation, polyol
pathway activity and PKC activity in experimental and
clinical diabetes [18,36]. The resultant changes in the re-
dox status of the cell are augmented by glucose-mediated
injury to mitochondria through excessive activation of gly-
colysis, further promoting a cycle of oxidative stress and
cellular injury [37]. These pathways are summarized in
Figure 1.
Advanced Glycation Endproducts
(AGEs) and ROS Formation
Glycation is the result of non-enzymatic addition of
glucose or other saccharides to proteins, lipids and
nucleotides [36]. Glucose can bind to protein amino
groups which first form a shift base that then progress to an
Amadori product and result in the formation of AGEs and
subsequent cross linking of proteins [38]. While formation
of a shift base and an Amadori product are reversible, for-
mation of AGEs is irreversible. In diabetes, excess glucose
results in accelerated AGE production [36]. AGE forma-
tion in cells leads to intra and extracellular cross linking
of proteins and protein aggregation [39]. These reactions
require transition metal and ions as catalysts and deple-
tion of the transition metal capacity in diabetes may lead
to further AGE formation [36]. AGEs bind to a number of
receptor proteins, including the receptor for advance gly-
cation end products (RAGE) [40]. RAGE has multiple def-
inite downstream signaling targets and is the main receptor
through which AGE signaling is mediated. Downstream
signaling of AGE RAGE interaction include activation of
mitogen activated protein kinases (MAP kinases), p21 ras,
NFκB and multiple other intermediates [40]. When AGEs
interact with RAGE there is a production of reactive oxy-
gen species in part by activation of NADPH oxidase and
relocalization of pro-oxidant molecules at the cell surface
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Fig. 1. Mechanisms leading to oxidative stress in hyperglycemia. The normal end-point of glucose metabolism is the generation of ATP from ADP. In
the presence of excess glucose ADP becomes rate-limiting, and the pathway becomes clogged. ROS then result at several points, including escape of
electrons in the mitochondrial transfer chain to generate superoxide, and NADH oxidase is activated also producing superoxide. When glycolysis
slows, fructose 1-6-bisphosphate is shunted into the hexosamine pathway that produces oxidative stress. Excess glucose is diverted to the polyol
pathway as well as activating intracellular and extracellular glycation reactions.
[41]. AGEs also cause a depletion of glutathione. If AGE
accumulation is blocked and/or AGE RAGE interaction is
prevented, there is a decrease in cellular oxidative stress
and a restoration of nerve conduction deficits in the strep-
tozotocin rat [36].
The Polyol Pathway
Excess glucose can be converted to sorbitol by aldose re-
ductase [13]. This first step in the polyol pathway is linked
to the oxidation of NADPH to NADP+. This leads to de-
pletion of NADPH needed for regenerating glutathione
[42]. Thus, early after the induction of diabetes, metabolic
defects lead to loss of NADPH, which limits the nerve’s
ability to scavenge reactive oxygen species, promoting a
vicious cycle of oxidative stress. Sorbitol accumulation
can also result in cellular osmotic stress that may alter the
anti-oxidant potential of the cell and increase ROS [34].
The aldose reductase pathway has been the target of mul-
tiple experimental and clinical studies. Aldose reductase
inhibitors have been successful in experimental diabetes,
however, they have not proven effective in clinical dia-
betes [7,34]. This could be due in part to the ability of the
drug to enter the nerve. Those aldose reductase inhibitors
that do penetrate the nerve do decrease nerve sorbitol lev-
els and in one clinical trial there is evidence of enhanced
axonal regeneration [43]. In parallel, recent genetic stud-
ies link polymorphisms of the aldose reductase gene to an
increased risk of diabetic complications [44].
PKC Activation
The role of PKC activity in the peripheral nervous system
is less clear than its well-established role in the retina, kid-
ney and the microvasculature [45]. It is generally held that
the potential effects of the PKC pathway on the pathogen-
esis of diabetic neuropathy is more likely due to its con-
tribution to vascular blood flow [46]. PKC is exquisitely
sensitive to a cell’s redox status. Anti-oxidants can bind the
catalytic domain of PKC and inhibit the enzyme’s activity.
In contrast, pro-oxidants interact with the regulatory do-
main of PKC to activate the enzyme [47]. PKC activation
results in MAP kinase activation and the phosphorylation
of transcription factors that can increase the gene expres-
sion of multiple cellular stress related genes such as c-Jun
kinases and the heat shock proteins [48]. These in turn
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can damage the cell. In streptozotocin diabetic rats, in-
hibition of PKC can normalize blood flow, restore nerve
conduction velocities and reduce nerve oxidative stress
[49]. There is currently an ongoing trial of a PKC blocker
in the treatment of a separate microvascular complication
of diabetes, retinopathy [45].
Mitochondria, Oxidative Stress, and ROS
In the diabetic state, AGE accumulation, polyol pathway
activity and PKC activation all lead to increased systemic
and nervous system oxidative stress. Augmenting all of
these processes is the generation of ROS under acute hy-
perglycemic episodes that over-activate the normal path-
way of glucose metabolism. Once a cell has achieved a
maximal level of ATP, oxidative phosphorylation shuts
down, and intermediates in the pathway accumulate [50].
Electrons escape from the electron transfer pathway to
produce superoxide. Excessive mitochondrial NADH is
converted back to NAD+ with the generation of super-
oxide as a by-product, and fructose-6-phosphate is di-
verted from glycolysis to the hexosamine pathway that
leads to inflammation and vascular disease. The net re-
sult of all these consequences of hyperglycemia is the
accumulation of ROS that leads to cellular damage and
eventually to cellular apoptosis [27,51]. This later apop-
totic process appears to occur in neurons via ROS me-
diated injury to mitochondria [27,28]. In cultured DRG
neurons, we have demonstrated how hyperglycemia pro-
duces apoptosis through mitochondrial oxidative stress
through a novel hypothesis involving uncoupling proteins.
Uncoupling proteins relieve hyperglycemia-induced elec-
tron transfer stress that produces mitochondrial hyperpo-
larization. DRG neurons express uncoupling protein 3
(UCP3), but this protein is downregulated in diabetes.
Increasing UCP3 expression decreases hyperglycemia-
induced superoxide formation and subsequent cell death
(Fig. 2).
There are two key events in apoptosis that occur at the
mitochondrial level: (1) mitochondrial permeability tran-
sition with change in mitochondrial membrane potential
(M) leading to mitochondrial membrane depolariza-
tion (MMD), and (2) release of proapoptotic factors like
cytochrome c and Ca2+ [27,52]. Mitochondrial permeabil-
ity transition occurs when large pores open in the inner mi-
tochondrial membrane; these pore openings cause osmotic
swelling, that in turn disrupt the integrity of the outer mito-
chondrial membrane and lead to changes in mitochondrial
membrane potential (M) [53]. These events culminate
in mitochondrial membrane depolarization (MMD) and
release of proapoptotic factors into the cytoplasm that
activate the caspase cascade [27,37]. Superoxide anion
is the major ROS generated in mitochondria. Superoxide
formation results in mitochondrial lipid, DNA and protein
peroxidation and nitrosylation that in turn leads to M
and MMD [18]. In the diabetic state, high glucose leads to
ROS formation in neurons followed by mitochondrial per-
meability transition, mitochondrial swelling, M and
MMD [27].
Our laboratory was the first group to propose glucose-
mediated apoptosis as a fundamental mechanism in di-
abetic complications, including neuropathy. We have
reported that apoptosis occurs in dorsal root ganglion neu-
rons (DRG) and Schwann cells (SC) from diabetic rats
[27]. Approximately 30% of DRG from diabetic rats ex-
press cleaved capsase-3 and are TUNEL positive. These
markers of apoptosis are confirmed by ultrastructural anal-
ysis with electron microscopy (EM). EM also reveals that
DRG from diabetic animals contain swollen mitochondria
with disrupted inner cristae structure [51]. Our observa-
tions in DRG from diabetic animals are corroborated by
other laboratories [37,54] and the concept of glucose in-
duced cell death as a mediator of diabetic complications
is now expanded to include other complication prone tis-
sues, including the retina, kidney, vascular endothelium,
and fibroblasts [25,55,56].
Oxidative Stress as the Final Common
Pathway in Neuropathy
In summary, unchecked, ROS produce (1) lipid, DNA
and protein peroxidation [57,58], (2) ischemia and re-
duced nerve blood flow [46,59], and (3) cellular apoptosis
[27,28,37,51]. These alterations in cellular metabolism re-
sult in peripheral nervous system damage and the signs and
symptoms of neuropathy [60].
In the diabetic rat, measures of oxidative stress
and reduced levels of circulating antioxidants parallel
neuropathy and blocking oxidative stress in the diabetic
animal prevents the development of neuropathy [58].
Antioxidants restore normal blood flow and sciatic and
saphenous nerve conduction velocities in STZ diabetic rats
[61,62]. Treatment with insulin decreases ROS activity in
diabetes and prevents experimental diabetic neuropathy
[63,64]. Growth factors may also serve as anti-oxidants
and this function may contribute to their role as possible
therapeutic entities in diabetic neuropathy [65,66].
In vitro, nerve growth factor (NGF) protects neuronal
cells from ROS-triggered apoptosis [67,68]. In parallel,
IGF-I also protects primary and transformed neurons from
oxidative stress and cell death [69,70]. The mechanism(s)
of action underlying the neuroprotective effects of
growth factors are unknown. These data in experimental
diabetes are paralleled by recent progress in clinical
diabetes.
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Fig. 2. A Increasing concentrations of glucose induce cleavage of caspase-3, oxidative stress and apoptosis that are blocked by uncoupling proteins.
(A) Increased glucose induces cleavage of caspase-3 in cultured DRG neurons. DRG neurons were cultured in control media (i) or media containing
20 mM added glucose (ii). After 6 h, the cultures were fixed and stained with 5 µg/ml CM1 to indicate cleaved (active) caspase-3 (orange-red), and 1
µg/ml bisbenzamide to indicate nuclear chromatin (blue). i. Immunofluorescent image showing normal diffuse nuclear staining in the DRG neuron
(blue). ii. Immunofluorescent image showing cleaved caspase-3 in the cytoplasm (white arrows) with some of the nuclei showing aggregation of
chromatin consistent with apoptosis (white arrowheads). ii shows high magnification of a single DRG neuron with punctate diffuse CM1 staining
(cleaved caspase-3) in the cytoplasm, with chromatin clumping consistent with dissolution of the nucleus (white arrow head). (B) A. DRG from 4 week
STZ diabetic rats were probed by Western blotting for UCP3 protein with probing for COX-IV as a loading control. DRG from 8 diabetic and 8
weight-matched control animals were used and protein concentration was equalized before loading. The blot illustrates 4 control and 4 diabetic rats.
The bar graph shows the mean UCP densitometry for 8 control and 8 diabetic (*diabetic<control animals, p < 0.01). (C) DRG neurons were infected
either with Ad.OMC (a mitochondrial protein; oxomaleate carrier) or Ad.UCP3 and exposed to high-glucose. Superoxide was assessed through
oxidation of DHE to ethidium. The ethidium:DHE ratio was significantly decreased in UCP compared with OMC overexpressing controls at the time
points shown (∗p < 0.01). (D) Cultured DRG neurons were infected with adenovirus containing UCP1, UCP3, or GFP for 24 h prior to the
application of 20 mM extra glucose or 20 mM osmotic control o-methyl glucopyranose (OMG). Neurons were then fixed at 6 h and stained for
caspase-3 cleavage. Caspase-3 staining in control GFP-expressing neurons increases in 20 mM added glucose, but not in the presence of 20 mM
OMG. In contrast, overexpression of UCP1 or UCP3 completely prevents caspase 3 cleavage caused by 20 mM added glucose. (Taken from
Russell et al. [27]; Vincent et al. [28])
Clinical Parameters of Oxidative
Stress in Diabetes
In type 1 patients, there is evidence of systemic oxida-
tive stress prior to the onset of micro or macrovascular
complications [35]. Thus, systemic and tissue parameters
of oxidative stress are assessed to determine the risk of
complications as well as the efficacy of therapeutic inter-
ventions. Antioxidant potential and biomarkers of peroxi-
dation correlate with the level of glycemic control [71]. As
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the duration of both type 1 and type 2 diabetes progresses,
patients show decreased antioxidant potential, although
consistent changes in individual antioxidant molecules are
not characterized [72]. Serum vitamins E and C tend to
decrease in diabetic patients, and the decrease is greater in
diabetic patients with angiopathy [73]. Diabetic patients
generally display increased SOD activity, plasma lipid per-
oxides, and glutathione peroxidase and reductase and a
decrease in GSH and α-tocopherol [74]. In contrast, af-
ter complications such as kidney disease develop, platelet
SOD activity decreases [75]. Another strong indicator of
diabetic kidney disease is the presence of the peroxidated
DNA adduct 8-OH-2-deoxyguanosine [76]. Urinary 8-
isoprostane F2α and plasma malondialdehyde generally
increase in diabetes [72]. Lipid peroxidation correlates
with AGE formation in type 2 diabetes and to a greater ex-
tent in type 1 diabetes [71]. Plasma protein carbonyls lipid
peroxidation, and non-protein thiol levels are all increased
to a greater extent in diabetes patients with complications
than diabetes patients with no complications [77].
Mechanistic Treatment of Diabetic
Neuropathy
Treatment strategies that halt oxidative stress decrease cell
injury and, in many cases, restore function in cell culture
and animal models of diabetic complications. Oxidative
stress therefore is a therapeutic target in the treatment of di-
abetic complications. Therapies may be designed to block;
(1) the initial phase of glucose-induced oxidative stress,
(2) the free radicals that are generated by oxidative stress,
or (3) the cellular damage produced by the accumulation
of free radicals. A second approach can involve enhanc-
ing the natural antioxidant response of the cell, making
it less susceptible to oxidative damage. Interestingly, dia-
betic patients with marked kidney disease tend to have an
impaired renal anti-oxidant response [75], suggesting that
innate ability to respond to oxidative stress may underlie
differential susceptibility to complications.
Clinical trials in diabetic patients reveal complex inter-
actions of drugs in the pathways of glycemic control and
oxidative stress mechanisms. The widely-used glycemia
lowering drugs gliclazide and metformin possess addi-
tional in vivo anti-oxidant properties [78]. Attributing the
prevention of diabetic complications to anti-oxidant ef-
fects rather than reduced hyperglycemia is difficult to
prove. One study compared the effects of gliclazide that
promotes anti-oxidant status with glibenclamide that is not
an anti-oxidant [59]. Gliclazide but not glibenclamide im-
proves both plasma anti-oxidant potential and nitric oxide-
mediated vasodilation in type 2 diabetic patients. Despite
difficulty of interpretation in many cases, the abundance
of antioxidant therapy trials makes a strong case for the
importance of oxidative stress in the development of dia-
betes complications.
Very few studies have examined neuropathy as an end-
point for therapeutic benefit in antioxidant clinical trials.
The most widely studied antioxidant in this area is α-lipoic
acid. This compound is approved for the prevention of di-
abetic neuropathy in Europe [79]. Ongoing examinations
of cohorts of patients demonstrate decreased neuropathic
symptoms including pain, paresthesia, and numbness with
600 mg/d doses [80]. Patients receiving 1200 mg/d have
greater improvement in these symptoms, but increased ad-
verse effects. Beneficial effects are noted even in patients
with poor glycemic control [81]. α-Lipoic acid is both fat
and water-soluble, and so decreases oxidation in multiple
tissues and plasma through recycling other antioxidants
and chelating transition metals [82].
Vitamin E is a lipid phase antioxidant that also can im-
prove insulin action and decrease glycated hemoglobin
[83]. α-Tocopherol (the major dietary vitamin E sup-
plement) was applied in a small double blind placebo-
controlled trial in diabetic patients with moderately
severe neuropathic symptoms [84]. The trial demon-
strated improvements in nerve conduction velocity. Elec-
trophysiological testing was performed at the start and
after 6 mo treatment with 900 mg/d vitamin E or
placebo.
Vitamin C is the most prominent antioxidant in the
plasma. As such, it is not expected to provide signifi-
cant benefit directly against neuropathy, although chronic
administration, greater than 4 mo, of 1g/day vitamin C
not only decreases plasma free radicals but also leads
to increases in cellular GSH [85]. Generally, vitamin C
is applied in clinical trials in combination with other
antioxidants.
As already stated, many antioxidants have been clini-
cally tested in diabetes, but neuropathy itself was not ex-
amined. Since the same mechanisms that produce cellular
injury through oxidative stress are likely to mediate neu-
ropathy, we include a list of some of the more common
antioxidants. Allopurinol [86] and flavonoids [87] are both
biologically active antioxidants. In clinical trials these cor-
rect plasma oxidative deficits such as plasma lipid per-
oxidation, and decreased plasma HbA1c without altering
plasma glucose. L-Arginine decreases evidence of urinary
lipid peroxidation [88], and zinc that promotes the levels
of glutathione peroxidase also promotes plasma antiox-
idant potential [89]. Many further clinical studies of α-
lipoic acid and vitamins E and C have demonstrated lower
plasma lipid peroxidation and urinary 8-isoprostanes [90],
with α-lipoic acid being the most potent. These com-
pounds also reduce oxidative stress in the eye [91] and
improve vascular function [92].
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Fig. 3. The pathway leading to diabetic neuropathy presents several
therapeutic targets. Overwhelming evidence that
hyperglycemia-induced oxidative stress is key to the development of
diabetic neuropathy suggests multiple therapeutic targets.
Combination therapies aimed at multiple targets, therefore, should
provide potent protection against this devastating disease.
To date, a thorough examination of long-term anti-
oxidant therapy with correlations to glycemia control, ox-
idative stress, and neuropathy has not been completed.
Despite this lack we have demonstrated an abundance of
evidence supporting the need to promote anti-oxidant sta-
tus in diabetic patients. An increasing literature describes
the potential to regulate the innate anti-oxidant response,
although no conclusive evidence for a therapeutic benefit
against diabetic neuropathy has been presented [93]. Be-
cause anti-oxidant systems are intricately balanced, and
since novel strategies to promote anti-oxidant status are
under development, we anticipate that combination thera-
pies targeting multiple anti-oxidant systems will produce
a breakthrough in the treatment and prevention of diabetic
neuropathy (Fig. 3).
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